Targeting VISTA has shown great promise in multiple preclinical models and can decrease myeloid suppression of immune responses as well as induce proinflammatory changes in the tumour microenvironment by mechanisms different from PD-1 and CTLA-4 blockade [19]. The gene discussed is CTLA4; the disease is neoplasm.